AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01399008
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 mg colchicine daily as flare prophylaxis
Trial: NCT00664326
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
Trial: NCT00892359
Drug: Anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
Trial: NCT02965885
Drug: TAS-116
RxNorm normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
Trial: NCT00005875
Drug: rubitecan
RxNorm normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01660893
Drug: Tetracaine HCl 3%
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 unilateral intranasal sprays per dose
Trial: NCT01883011
Drug: Piracetam
RxNorm normalized name: Piracetam
DrugBank: Piracetam (DB09210)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00017134
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03090100
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
Trial: NCT02127034
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02127034
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02127034
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03090100
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
Trial: NCT02965443
Drug: Dapagliflozin 10 mg + Saxagliptin 5 mg
RxNorm normalized name: dapagliflozin / sAXagliptin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
Trial: NCT01458899
Drug: TC-5214
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, single 4mg dose
Trial: NCT02506816
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
Trial: NCT02212587
Drug: TOBI
RxNorm normalized name: Tobi
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
Trial: NCT02750891
Drug: DSP-7888
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
Trial: NCT01652664
Drug: Travoprost 0.004% PQ ophthalmic solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01652664
Drug: Timolol, 0.5% or 0.25% ophthalmic solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients 2 months to \< 3 years of age received 0.25%
Trial: NCT01652664
Drug: Travoprost Vehicle
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inactive ingredients used to maintain masking
Trial: NCT02357069
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept
Trial: NCT00297037
Drug: Pimecrolimus 1% cream
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pimecrolimus cream or matching placebo BID for 6 weeks
Trial: NCT00668941
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
Trial: NCT00668941
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take 70 mg per week of alendronate for 48 months.
Trial: NCT00206453
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy IV
Trial: NCT00528723
Drug: salbutamol 100 mcg
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be used as needed for symptom relief
Trial: NCT03307629
Drug: NOX66
RxNorm normalized name: Noxafil
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NOX66 delivered as rectal suppository.
Trial: NCT00069992
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30mg/m2 Day -5 to -2
Trial: NCT02212678
Drug: N-acetylcysteine capsule
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine capsule
Trial: NCT03166111
Drug: lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
Trial: NCT03591172
Drug: Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using propolis as a final irrigation in revascularization
Trial: NCT03591172
Drug: Nano-propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using Nano-propolis as a final irrigation in revasculariztion
Trial: NCT03591172
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using saline as a final irrigation in revasculariztion
Trial: NCT02753127
Drug: Napabucasin
RxNorm normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
Trial: NCT02753127
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02753127
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01670565
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
Trial: NCT01670565
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
Trial: NCT03694873
Drug: Tramadol Hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
Trial: NCT02229942
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months.
Trial: NCT02694146
Drug: Platelet rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
Trial: NCT01837628
Drug: Lidocaine Gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01837628
Drug: Paraffin Oil
RxNorm normalized name: Paraffin Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01549964
Drug: Fasiglifam (TAK-875)
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam (TAK-875) tablets
Trial: NCT01549964
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin tablets
Trial: NCT02972632
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine tablet
Trial: NCT01041872
Drug: Propofol Astrazeneca plain
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Trial: NCT01041872
Drug: Propofol Astrazeneca plus lidocaine
RxNorm normalized name: Propofol
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Trial: NCT01041872
Drug: Propofol-lipuro B. Braun plain
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Trial: NCT01041872
Drug: Propofol-lipuro B. Braun plus lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Trial: NCT01041872
Drug: Propofol Fresenius plain
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
Trial: NCT01041872
Drug: Propofol Fresenius plus lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Trial: NCT03211949
Drug: Scandicaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
Trial: NCT00370253
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/4 h per day
Trial: NCT00370253
Drug: Noradrenalin
RxNorm normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,1 mcg/kg/min
Trial: NCT00232310
Drug: CELIVARONE (SSR149744C)
RxNorm normalized name: Celivarone
DrugBank: Celivarone (DB16012)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001893
Drug: TNFR:Fc
RxNorm normalized name: rhu TNFR:Fc
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00579111
Drug: Campath
RxNorm normalized name: Campath
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
Trial: NCT00579111
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
Trial: NCT00579111
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2/day IV daily for 4 days on Day -5 to D -2
Trial: NCT00579111
Drug: FK-506
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
Trial: NCT04327999
Drug: Artificial Tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Administered - utilizing eye drop preservative free vials
Trial: NCT00129363
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00532285
Drug: Paclitaxel/Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
Trial: NCT01430013
Drug: Endostar and CHOPT
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
Trial: NCT01498952
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
Trial: NCT00579826
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
Trial: NCT02105974
Drug: Fluticasone Furoate/Vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
Trial: NCT02060032
Drug: 1.2% Atorvastatin local drug delivery
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00440310
Drug: Talaporfin sodium
RxNorm normalized name: Talaporfin
DrugBank: Talaporfin (DB11812)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Trial: NCT00044187
Drug: Sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01650415
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a week for 1 month
Trial: NCT01650415
Drug: Placebo erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a week for 1 month
Trial: NCT01513681
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine Tablets 200 mg
Trial: NCT00697437
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg q3wx 1 dose
Trial: NCT00697437
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
Trial: NCT04566653
Drug: Lokelma® 5 g/45mL water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Trial: NCT04566653
Drug: Lokelma® 10 g/45 mL water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Trial: NCT04566653
Drug: Veltassa® 8,4 g/80mL water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Trial: NCT04566653
Drug: Sodium Polystyrene Sulphonate 15g/60 mL water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ binder, not for treatment but for tasting (sip-and-spit taste test)
Trial: NCT00149019
Drug: Cell therapy with bispecific antibodies
RxNorm normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01352637
Drug: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
RxNorm normalized name: DCS
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Trial: NCT01352637
Drug: DCS (D-Cycloserine ) + Virtual Reality Exposure
RxNorm normalized name: DCS
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Trial: NCT00289809
Drug: combination of TLC D-99 and Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks
Trial: NCT02537405
Drug: Rivaroxaban (BAY 59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban granule 10mg for one day
Trial: NCT02537405
Drug: Rivaroxaban (Xarelto, BAY 59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban tablet 10mg for one day
Trial: NCT00136968
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00624676
Drug: 5% benzoyl peroxide gel
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day
Trial: NCT02120976
Drug: JTT-252 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive JTT-252 or Placebo
Trial: NCT02120976
Drug: JTT-252
RxNorm normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive JTT-252
Trial: NCT00003814
Drug: eflornithine
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00363454
Drug: Triciribine Phosphate Monohydrate
RxNorm normalized name: Triciribine phosphate
DrugBank: Triciribine (DB12405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
Trial: NCT03902080
Drug: Vibegron
RxNorm normalized name: Vibegron
DrugBank: Vibegron (DB14895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral administration
Trial: NCT00332709
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day for 3 years